Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS
- 13 July 2013
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (10) , 3233-3239
Abstract
Patients with estrogen-independent (ERneg) human epidermal growth factor receptor-2 (HER-2)-positive ductal carcinoma in situ (DCIS) treated with lumpectomy alone or lumpectomy and radiation are at increased risk of developing subsequent breast cancer events. Thirty-eight patients with HER-2 expressing DCIS received a HER-2 pulsed autologous dendritic cell (DC1) vaccine administered over 4–6 weeks before surgical resection. HER-2 and estrogen receptor (ER) expression were determined by immunohistochemistry. In 35 patients, CD4pos T-cell sensitization to HER-2 peptides was identified by ELISPOT. In 19 patients, CD8pos T-cell responses were identified by ELISA. Clinical and immune responses postvaccination were compared between intermediate-expressing HER-2 (2+) and high-expressing HER-2 (3+) patients, as well as ERneg and estrogen-dependent (ERpos) patients. There was no significant difference in immune response after HER-2 vaccination in patients with HER-2 (2+) and (3+) tumors or ERneg and ERpos tumors. Complete tumor regression rates were similar in patients with HER-2 (2+) and (3+) DCIS. Overall, clinical response rates were similar in patients with ERneg and ERpos DCIS, but complete tumor regression was significantly more common in patients with ERneg DCIS. Despite equivalent immune responses after vaccination in patients with HER-2 (2+), HER-2 (3+), ERneg and ERpos DCIS, HER-2 pulsed DC1 induces more complete responses in patients with ERneg DCIS. These data provide a rationale for developing vaccinations to reduce recurrence in patients with ERneg DCIS for whom there are currently limited adjuvant options.Keywords
This publication has 21 references indexed in Scilit:
- Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersBreast Cancer Research and Treatment, 2012
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast CancerJournal of Immunotherapy, 2012
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- The significance of HER‐2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive diseaseJournal of Surgical Oncology, 2011
- Recent Developments in Cancer VaccinesThe Journal of Immunology, 2011
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer StudyClinical Cancer Research, 2010
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2009
- Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to EstrogenCancer Research, 2009